company background image

Xeris Biopharma Holdings NasdaqGS:XERS Stock Report

Last Price


Market Cap







24 Mar, 2023


Company Financials +

Xeris Biopharma Holdings, Inc.

NasdaqGS:XERS Stock Report

Mkt Cap: US$175.7m

XERS Stock Overview

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois.

XERS fundamental analysis
Snowflake Score
Future Growth2/6
Past Performance0/6
Financial Health2/6

My Notes

Capture your thoughts, links and company narrative

Xeris Biopharma Holdings, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Xeris Biopharma Holdings
Historical stock prices
Current Share PriceUS$1.28
52 Week HighUS$2.88
52 Week LowUS$0.97
1 Month Change2.40%
3 Month Change1.59%
1 Year Change-54.77%
3 Year Changen/a
5 Year Changen/a
Change since IPO-45.76%

Recent News & Updates

Recent updates

Xeris Pharmaceuticals Q2 2022 Earnings Preview

Aug 09

Xeris amends commercial terms for hypoglycemia therapy as partner inks buyout deal

Aug 01

Xeris Biopharma: Q1 Earnings Reveal Path To Breakeven

May 21

Xeris Continues To Execute And Build Long-Term Value Potential

Feb 22

Xeris Biopharma: Market Is Snubbing The Strongbridge Acquisition

Dec 20

Shareholder Returns

XERSUS PharmaceuticalsUS Market

Return vs Industry: XERS underperformed the US Pharmaceuticals industry which returned -6.1% over the past year.

Return vs Market: XERS underperformed the US Market which returned -14.8% over the past year.

Price Volatility

Is XERS's price volatile compared to industry and market?
XERS volatility
XERS Average Weekly Movement12.0%
Pharmaceuticals Industry Average Movement10.8%
Market Average Movement6.5%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.0%

Stable Share Price: XERS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: XERS's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

2005355Paul Edick

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company markets Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect.

Xeris Biopharma Holdings, Inc. Fundamentals Summary

How do Xeris Biopharma Holdings's earnings and revenue compare to its market cap?
XERS fundamental statistics
Market CapUS$175.73m
Earnings (TTM)-US$94.66m
Revenue (TTM)US$110.25m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
XERS income statement (TTM)
Cost of RevenueUS$22.63m
Gross ProfitUS$87.61m
Other ExpensesUS$182.27m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date


Earnings per share (EPS)-0.69
Gross Margin79.47%
Net Profit Margin-85.86%
Debt/Equity Ratio414.0%

How did XERS perform over the long term?

See historical performance and comparison